Predicting Myelosuppression of Drugs from in Silico Models

Anticancer agents targeting proliferating cell populations in tumor as well as in normal tissues can lead to a number of side effects including hematotoxicity, a common dose-limiting toxicity associated with oncology drugs. Myelosuppression, regarded as unacceptable for other therapeutic indications, is considered a clinical risk also for new targeted anticancer drugs acting specifically on tumor cells. Thus, it becomes important not only to evaluate the potential toxicity of such new therapeutics to human hematopoietic tissue during preclinical development but also to anticipate this liability in early drug discovery. This could be achieved by using in silico models to guide the design of new lead compounds and the selection of analogs with reduced myelosuppressive potential. Hence, the purpose of this study was to develop computational models able to predict the potential myelotoxicity of drugs from their chemical structure. The data set analyzed included 38 drugs. The structural diversity and the drug-like space covered by these molecules were investigated using the ChemGPS methodology. Two sets of potentially relevant descriptors for modeling myelotoxicity (i.e., 3D Volsurf+ and 2D structural and electrotopological E-states descriptors) were selected and a Principal Component Analysis was carried out on the entire set of data. The first two PCs were able to discriminate the highest from the least myelotoxic compounds with a total accuracy of 95%. Then, a quantitative PLS model was developed by correlating a selected subset of in vitro hematotoxicity data with Volsurf+ descriptors. After variable selection, the PLS analysis resulted in a one-latent-variable model with r(2) of 0.79 and q(2) of 0.72. The inclusion of 2D descriptors in the PLS analysis improved only slightly the robustness and quality of the model that predicted the pIC(50) values of 21 drugs not included in the model with a RMSEP of 0.67 and a squared correlation coefficient (r(0)(2)) of 0.70. Furthermore, in order to investigate whether the highly myelotoxic compounds are characterized by common structural features, which should be taken into consideration in the design of new candidate drugs, the entire data set was analyzed using GRIND toxicophore-based descriptors. One toxicophore emerged from the interpretation of the model. The toxicophore elements, at least determined by the molecules used in this study, are a pattern of H-bond acceptor groups, presence of a H-bond donor and H-bond acceptor regions at ∼15 Å distance and a hydrophobic and H-bond acceptor interacting regions separated by a distance of ∼12.4 Å. Moreover, the dimensions of the molecule play a role in its recognition as a myelotoxic compound.

[1]  Tudor I. Oprea,et al.  Chemography: the Art of Navigating in Chemical Space , 2000 .

[2]  C. Jun,et al.  Performance of some variable selection methods when multicollinearity is present , 2005 .

[3]  Paul Geladi,et al.  Principal Component Analysis , 1987, Comprehensive Chemometrics.

[4]  M. Ghielmini,et al.  Predicting hematological toxicity (myelosuppression) of cytotoxic drug therapy from in vitro tests. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  Tudor I. Oprea,et al.  Chemical information management in drug discovery: optimizing the computational and combinatorial chemistry interfaces. , 2000, Journal of Molecular Graphics and Modelling.

[6]  Manuel Pastor,et al.  Development and Validation of AMANDA, a New Algorithm for Selecting Highly Relevant Regions in Molecular Interaction Fields , 2008, J. Chem. Inf. Model..

[7]  Tudor I. Oprea,et al.  Pharmacokinetically based mapping device for chemical space navigation. , 2002, Journal of combinatorial chemistry.

[8]  S. Pickett,et al.  GRid-INdependent descriptors (GRIND): a novel class of alignment-independent three-dimensional molecular descriptors. , 2000, Journal of medicinal chemistry.

[9]  R. Parchment Alternative testing systems for evaluating noncarcinogenic, hematologic toxicity. , 1998, Environmental health perspectives.

[10]  I. Rich High-throughput in vitro hemotoxicity testing and in vitro cross-platform comparative toxicity , 2007, Expert opinion on drug metabolism & toxicology.

[11]  R. Parchment,et al.  Roles for In Vitro Myelotoxicity Tests in Preclinical Drug Development and Clinical Trial Planning , 1993, Toxicologic pathology.

[12]  L. Hall,et al.  Three new consensus QSAR models for the prediction of Ames genotoxicity. , 2004, Mutagenesis.

[13]  I. Rich In vitro hematotoxicity testing in drug development: a review of past, present and future applications. , 2003, Current opinion in drug discovery & development.

[14]  P. Carrupt,et al.  Molecular fields in quantitative structure–permeation relationships: the VolSurf approach , 2000 .

[15]  Ferran Sanz,et al.  Incorporating molecular shape into the alignment-free Grid-Independent Descriptors. , 2004, Journal of medicinal chemistry.

[16]  D. Metcalf,et al.  The growth of mouse bone marrow cells in vitro. , 1966, The Australian journal of experimental biology and medical science.

[17]  P. Crivori,et al.  Assessment of QT liabilities in drug development , 2006, Cell Biology and Toxicology.

[18]  I. Rich,et al.  Validation and development of a predictive paradigm for hemotoxicology using a multifunctional bioluminescence colony-forming proliferation assay. , 2005, Toxicological sciences : an official journal of the Society of Toxicology.

[19]  S. Wold,et al.  PLS: Partial Least Squares Projections to Latent Structures , 1993 .

[20]  L. Eriksson Multi- and megavariate data analysis , 2006 .

[21]  D Parent-Massin,et al.  Application of the CFU-GM assay to predict acute drug-induced neutropenia: an international blind trial to validate a prediction model for the maximum tolerated dose (MTD) of myelosuppressive xenobiotics. , 2003, Toxicological sciences : an official journal of the Society of Toxicology.

[22]  Lemont B. Kier,et al.  Electrotopological State Indices for Atom Types: A Novel Combination of Electronic, Topological, and Valence State Information , 1995, J. Chem. Inf. Comput. Sci..

[23]  L. Sachs,et al.  The induction of clones of normal mast cells by a substance from conditioned medium. , 1966, Experimental cell research.

[24]  D. Parent-Massin,et al.  Prevalidation of a model for predicting acute neutropenia by colony forming unit granulocyte/macrophage (CFU-GM) assay. , 2001, Toxicology in vitro : an international journal published in association with BIBRA.